FDA approves GSK's combo prostate drug

NEW YORK The Food and Drug Administration has approved a new combination drug from GlaxoSmithKline to treat enlarged prostate.

The drug combines Avodart, known generically as dutasteride, and Flomax, known generically as tamsulosin. Clinical data have shown that both medicines together treat enlarged prostate better than either medicine alone.

Avodart treats urinary symptoms associated with enlarged prostate, while Flomax treats the signs and symptoms of the disease. Avodart had sales of about $562 million in 2007, according to GSK financial data.